Peter Kern1,2, Anne Kalisch1, Gunter von Minckwitz2, Carolin Pütter3, Hans-Christian Kolberg4, Dirk Pott5, Christian Kurbacher6, Mahdi Rezai7, Rainer Kimmig1. 1. a Universitat Duisburg-Essen, University Hospital of Essen, Women's Department , Düsseldorf , Germany. 2. b GBG Forschungs GmbH, German Breast Group , Neu-Isenburg , Germany. 3. c Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), Universitat Duisburg-Essen , Germany. 4. d Marienhospital Bottrop, Women's Department , Germany. 5. e Clinic of Hematology and Oncology , Bottrop , Germany. 6. f Medical Center Bonn Friedensplatz , Germany. 7. g European Breast Center Düsseldorf, Luisen Hospital , Germany.
Abstract
INTRODUCTION: Triple-negative breast cancer (TNBC) has the highest mortality rates of all subtypes. Anthracycline and taxane regimens yield unsatisfactorily low rates of pathologic complete response (pCR) and are often not feasible in cardiac comorbidity. This study seeks to increase pCR and survival by introducing platin agents. PATIENTS AND METHODS: In this multicentric, open-label study with six cycles of docetaxel (75 mg/m(2)) and carboplatin AUC 6 q3w, patients were unwilling or unsuitable for anthracycline-based regimens. Primary endpoint was pCR (ypT0/ypTis ypN0) and survival. RESULTS: pCR rate was 50%. After 2 and 5 years, overall survival (OS) was 96.7 and 89.7%, disease-free-survival (DFS) 96.7 and 85.7%, DDFS 96.7 and 89.6%. Grade 3/4 toxicities were rare. Ninety-three per cent of patients completed six cycles. No toxicity-related treatment discontinuation or febrile neutropaenia was recorded. CONCLUSION: This regimen is highly effective and feasible in TNBC and may be combined with anthracyclines.
INTRODUCTION: Triple-negative breast cancer (TNBC) has the highest mortality rates of all subtypes. Anthracycline and taxane regimens yield unsatisfactorily low rates of pathologic complete response (pCR) and are often not feasible in cardiac comorbidity. This study seeks to increase pCR and survival by introducing platin agents. PATIENTS AND METHODS: In this multicentric, open-label study with six cycles of docetaxel (75 mg/m(2)) and carboplatin AUC 6 q3w, patients were unwilling or unsuitable for anthracycline-based regimens. Primary endpoint was pCR (ypT0/ypTis ypN0) and survival. RESULTS: pCR rate was 50%. After 2 and 5 years, overall survival (OS) was 96.7 and 89.7%, disease-free-survival (DFS) 96.7 and 85.7%, DDFS 96.7 and 89.6%. Grade 3/4 toxicities were rare. Ninety-three per cent of patients completed six cycles. No toxicity-related treatment discontinuation or febrile neutropaenia was recorded. CONCLUSION: This regimen is highly effective and feasible in TNBC and may be combined with anthracyclines.
Entities:
Keywords:
Anthracycline-free; Carboplatin; Docetaxel; Pathological complete response; Survival; Triple-negative breast cancer
Authors: Isabel Echavarria; Sara López-Tarruella; Antoni Picornell; Jose Ángel García-Saenz; Yolanda Jerez; Katherine Hoadley; Henry L Gómez; Fernando Moreno; María Del Monte-Millan; Iván Márquez-Rodas; Enrique Alvarez; Rocío Ramos-Medina; Javier Gayarre; Tatiana Massarrah; Inmaculada Ocaña; María Cebollero; Hugo Fuentes; Agusti Barnadas; Ana Isabel Ballesteros; Uriel Bohn; Charles M Perou; Miguel Martin Journal: Clin Cancer Res Date: 2018-01-29 Impact factor: 12.531
Authors: Catharina Bartmann; Sudha R Janaki Raman; Jessica Flöter; Almut Schulze; Katrin Bahlke; Jana Willingstorfer; Maria Strunz; Achim Wöckel; Rainer J Klement; Michaela Kapp; Cholpon S Djuzenova; Christoph Otto; Ulrike Kämmerer Journal: Cancer Metab Date: 2018-06-11
Authors: Foluso O Ademuyiwa; Ina Chen; Jingqin Luo; Mothaffar F Rimawi; Ian S Hagemann; Bryan Fisk; Gejae Jeffers; Zachary L Skidmore; Anamika Basu; Megan Richters; Cynthia X Ma; Katherine Weilbaecher; Jennifer Davis; Rama Suresh; Lindsay L Peterson; Ron Bose; Nusayba Bagegni; Caron E Rigden; Ashley Frith; Timothy P Rearden; Leonel F Hernandez-Aya; Anna Roshal; Katherine Clifton; Mateusz Opyrchal; Olaronke Akintola-Ogunremi; Byung Ha Lee; Sara Ferrando-Martinez; Sarah E Church; Meenakshi Anurag; Matthew J Ellis; Feng Gao; William Gillanders; Obi L Griffith; Malachi Griffith Journal: Breast Cancer Res Treat Date: 2021-06-26 Impact factor: 4.624